2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 260-262
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Young Adult
PAPER

307 Epidemiology and predictors of late severe infections after CAR T-cell therapy

Sigrun Einarsdottir, MD, PhD, Teng Fei, PhD2, Danny Luan3, Kayleen Shi4, Samar Shamas5, Ofrat Beyar-Katz, MD, PhD6, Niveen Shibli7, Hazim Khatib, MD8, Jabour Halloun, MD9, Marina Gomez-Llobell, MD10, Silvia Escribano Serrat, MD11, Maria Isabel Sotelo, MD12, Alessandro Criscimanna13, Candela Ceballos14, Aditya Anand15, Michael Scordo, MD16, Jaime Sanz, MD, PhD17, Michael Von Bergwelt, Prof. Dr. med.18, Veit Leonhard Buecklein, MD, PhD19, Maximilian Merz, MD20, Sham Mailankody, MBBS21, Malin Hultcrantz, MD PhD22, Genovefa Papanicolaou23, Susan K. Seo24, Saad Z. Usmani, MD25, Mini Kamboj26, Marion Subklewe I, MD27, Gunjan L. Shah, MD, MS28, Jae H Park, MD29, Miguel-Angel Perales, MD30, Zainab Shahid, MBBS31, Roni Shouval Jr, MD, PhD32, Kai Rejeski, MD33
1 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States
3 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
4 Department of Medicine III, Hematology/Oncology, Munich, Germany
5 Department of Medicine III, Hematology/Oncology, Munich, Germany
6 Division of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
7 Division of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
8 Division of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
9 Division of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
10 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
11 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
12 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
13 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
14 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
15 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
16 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
17 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
18 Department of Medicine III, Hematology/Oncology, Munich, Germany
19 Department of Medicine III, Hematology/Oncology, Munich, Germany
20 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, United States
21 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, United States
22 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, United States
23 Infectious disease service, Memorial Sloan Kettering Cancer Center, New York, United States
24 Infectious disease service, Memorial Sloan Kettering Cancer Center, New York, United States
25 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, United States
26 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, United States
27 Department of Medicine III, Hematology/Oncology, Munich, Germany
28 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
29 Cellular therapy service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, United States
31 Infectious disease service, Memorial Sloan Kettering Cancer Center, New York, United States
32 Cellular therapy service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
33 Department of Medicine III, Hematology/Oncology, Munich, Germany

Introduction. Infection is a leading cause of morbidity and non-relapse mortality after CAR T-cell therapy. Most available data describe the early post-infusion period; whether and how this risk persists beyond day +30, when clinical vigilance and prophylaxis typically decrease, is not well characterized. Here, we aimed to define the late infectious landscape after CAR T-cell therapy and identify risk-factors for late infections.

Methods. We retrospectively studied adults with lymphoma or multiple myeloma who received commercial CAR T-cell therapy at two high-volume centers in the US and Germany from 2018-2025. Infections occurring until next-line therapy, death, or last follow-up were adjudicated by CAR-T specialized hematologists, with complex cases reviewed by infectious disease physicians. All episodes were graded by CTCAE, and classified by etiology as bacterial, viral, fungal, protozoal, or clinically defined according to BMT-CTN criteria. Analyses used a day +30 landmark, with a ±7-day window for laboratory and immune measurements. The primary endpoint was first severe infection (grade ≥3) after day +30 through day +365, with death as a competing event. Nonredundant factors associated with the endpoint in univariable analyses were entered into a multivariable Fine-Gray model. The association between severe infection during days +31-100 and subsequent OS was evaluated using a day +100 landmark Cox model.

Results. We analyzed 780 CAR T-cell recipients (median age, 65 years; 64% male) with large B-cell lymphoma (65%), multiple myeloma (18%), mantle-cell lymphoma (10%), or other indications. Products included axi-cel (36%), liso-cel (23%), tisa-cel (15%), cilta-cel (11%), ide-cel (8%), and brexu-cel (7%). Overall, 1,601 infectious episodes occurred across 575 patients, 60% of the patients had ≥2 episodes (median infections 2, IQR 1-3).

655 infections occurred after day +30 through day +365, including 214 (33%) severe infections. Late severe infections were most commonly clinically documented (38%; most commonly pneumonia without a microbiologic finding), bacterial (31%), or viral (28%). Almost half (48%) involved the lower respiratory tract and 22% were bloodstream infections (BSIs). Among late infections, 57 (9%) were vaccine-preventable illnesses: influenza (n=26), RSV (n=20), VZV/zoster (n=9), and pneumococcus (n=2), of which 16 were severe. Twenty-one infection-related deaths occurred: fungal (n=6), clinically defined (n=6), viral (n=5), and bacterial (n=4). An additional 444 infectious episodes occurred beyond one year.

Among 717 patients alive and free of next-line therapy at the day +30 landmark, the cumulative incidence of a first severe infection from day +30 onward was 12% by day +100, 18% by day +180, and 26% by day +365; 146 patients developed at least one severe late infection. Severe infection during days +31-100 was independently associated with inferior subsequent OS after adjustment for age and diagnosis (HR, 1.71; 95% CI, 1.08-2.71).

On univariable analysis, mantle-cell lymphoma, higher early ICAHT grade, a history of ICANS, higher cumulative corticosteroid exposure in the first 30 days, a history of early severe infection (day -5 to +30), day-30 ANC <0.5×10⁹/L, day-30 ALC <0.5×10⁹/L, and low day-30 IgG were associated with increased risk of late severe infection, whereas higher day-30 IgA was protective.

Among factors consistently available across both centers, mantle-cell lymphoma (HR, 1.99; 95% CI, 1.25-3.18), higher early ICAHT grade (HR per grade, 1.30; 95% CI, 1.10-1.54), a history of ICANS (HR, 1.64; 95% CI, 1.12-2.39), and day-30 ALC <0.5×10⁹/L (HR, 1.83; 95% CI, 1.26-2.67) remained independently associated with late severe infection in a multivariable model adjusted for age. Additional adjustment for center did not materially change the findings.

Conclusions. This study represents one of the largest and most granular analyses of infections after CAR T-cell therapy. Severe infections remained common beyond day +30, affecting 26% of patients by 1 year and contributing to substantial mortality. Pneumonias dominated the late severe infections. Invasive fungal infections were uncommon but had high mortality. Routinely available clinical and hematologic factors identified patients at increased risk and may inform future risk-adapted surveillance and preventive strategies.

Sigrun Einarsdottir, MD, PhD: Sanofi - Honoraria; MSD - Research Funding